文献速递帕金森病与运动障碍

静脉(DIZ101)、皮下(DIZ102)与肠道(LCIG)输注左旋多巴在晚期帕金森病中的药代动力学

Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease.
PubMed 文献 · Neurology · 2022-09-05

本随机、3周期交叉、开放标签、多中心试验比较了持续缓冲的酸性左旋多巴/卡比多巴溶液经静脉(DIZ101)或皮下(DIZ102)输注与已批准的LCIG在晚期帕金森病患者中的药代动力学。18例完成全部治疗的患者中,按估计生物利用度调整剂量后,DIZ101和DIZ102的左旋多巴血浆水平与LCIG相比在标准生物等效性范围内。皮下给予DIZ102达到治疗浓度与LCIG一样快,且在整个输注期间保持稳定。

要点

  • DIZ101和DIZ102与LCIG相比,左旋多巴血浆水平在标准生物等效性范围内。
  • DIZ102的左旋多巴生物利用度为完全,而LCIG为80%。
  • 皮下DIZ102达到治疗浓度与LCIG一样快,且输注期间保持稳定。

核心结论

  • 通过持续缓冲皮下给予的酸性左旋多巴/卡比多巴溶液,可快速达到高而稳定的左旋多巴浓度。

研究设计与样本

  • 随机、3周期交叉、开放标签、多中心试验,比较DIZ101、DIZ102与LCIG,制剂输注16小时。
  • 患者来自多家大学神经科诊所,但到同一I期病房接受治疗。
  • 18例参与者接受全部治疗,20例接受任何治疗者纳入安全性和耐受性评估。

主要发现

  • 按估计生物利用度调整剂量后,18例接受全部治疗的参与者中,DIZ101和DIZ102的左旋多巴血浆水平与LCIG相比在标准生物等效性范围内。
  • DIZ102的左旋多巴生物利用度为完全,而LCIG为80%。
  • 皮下给予DIZ102达到左旋多巴治疗浓度与LCIG一样快,且在整个输注期间保持稳定。
  • 由于LCIG吸收差,DIZ101和DIZ102的血浆卡比多巴水平高于LCIG。
  • 接受任何治疗的所有个体(n=20)中,输注部位反应为轻度且短暂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Intestinal levodopa/carbidopa gel infusion (LCIG) is superior to oral treatment in advanced Parkinson disease. The primary objective of this trial was to investigate whether continuous subcutaneous or intravenous infusion with a continuously buffered acidic levodopa/carbidopa solution yields steady-state plasma concentrations of levodopa that are equivalent in magnitude, and noninferior in variability, to those obtained with LCIG in patients with advanced Parkinson disease. METHODS: A concentrated acidic levodopa/carbidopa (8:1) solution buffered continuously and administered intravenously (DIZ101) or subcutaneously (DIZ102) was compared with an approved LCIG in a randomized, 3-period crossover, open-label, multicenter trial. Formulations were infused for 16 hours to patients with Parkinson disease who were using LCIG as their regular treatment. Patients were recruited from several university neurology clinics but came to the same phase I unit for treatment. Pharmacokinetic variables and safety including dermal tolerance are reported. The primary outcomes were bioequivalence and noninferior variability of DIZ101 and DIZ102 vs LCIG with respect to levodopa plasma concentrations. RESULTS: With dosing adjusted to estimated bioavailability, DIZ101 and DIZ102 produced levodopa plasma levels within standard bioequivalence limits compared with LCIG in the 18 participants who received all treatments. Although the levodopa bioavailability for DIZ102 was complete, it was 80% for LCIG. Therapeutic concentrations of levodopa were reached as quickly with subcutaneous administration of DIZ102 as with LCIG and remained stable throughout the infusions. Owing to poor uptake of LCIG, carbidopa levels in plasma were higher with DIZ101 and DIZ102 than with the former. All individuals receiving any of the treatments (n = 20) were included in the evaluation of safety and tolerability. Reactions at the infusion sites were mild and transient. DISCUSSION: It is feasible to rapidly achieve high and stable levodopa concentrations by means of continuous buffering of a subcutaneously administered acidic levodopa/carbidopa-containing solution. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov identifier: NCT03419806. Registration first posted on February 5, 2018, first patient enrolled on February 16, 2018.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bergquist F, Ehrnebo M, Nyholm D, et al. Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease. Neurology. 2022. PMID: 35705502. doi:10.1212/WNL.0000000000200804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。